Abstract
Substance use disorders (SUD) are associated with widespread brain structural alterations, but the principles governing their regional distribution remain unclear. We tested whether SUD-related morphometric differences are shaped by normative connectivity and neurotransmitter receptor architecture. We analysed T1-weighted MRI data from 2,782 individuals with SUD (mean age 34.6 years [SD 11.2]; 33.3% female) and 1,951 healthy controls (mean age 33.8 years [SD 12.0]; 37.5% female) across 51 ENIGMA Addiction Working Group sites, spanning alcohol, amphetamine, cannabis, cocaine, nicotine and opioid use disorders. Cortical thickness (68 regions) and subcortical volume (14 structures) were quantified using harmonized ENIGMA protocols. Case-control maps were related to normative functional and structural connectomes through hub-vulnerability and epicenter analyses, and to 20 PET-derived receptor-density maps using partial least squares analysis.
Across substances, SUD was associated with lower cortical thickness and subcortical volume involving frontal, parietal, temporal and limbic regions. Alterations overlapped with cortical hubs and converged on cortical and subcortical epicenters, with findings robust across six substances, biological sex and analytical approaches. SUD epicenters showed strong spatial overlap with those of schizophrenia and bipolar disorder, particularly in frontotemporal, parietal and striatal regions, distinct from mood, neurodevelopmental and obsessive-compulsive conditions. Cortical alteration patterns aligned with two neurochemical axes: one enriched in cannabinoid, opioid, metabotropic glutamate and histamine receptors, and another associated with lower dopaminergic and cholinergic marker density.
These findings indicate that addiction-related brain differences are organized by normative connectome and neurotransmitter architecture, providing a systems-level framework for identifying receptor- and circuit-based targets for intervention in addiction.
Competing Interest Statement
MK has received consulting fees from Otsuka for activities unrelated to the present study. All other authors declare that they have no conflicts of interest related to this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participating sites obtained approval from their respective local Ethics Committees or Institutional Review Boards, and all participants provided written informed consent in accordance with local regulations. Data were de-identified prior to sharing and analyzed in accordance with consortium-level data sharing agreements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revised version updates the neurotransmitter receptor mapping analysis and Figure 6. The partial least squares methods were clarified, including the computation and interpretation of SUD-side latent variable scores, variable loadings, and spatial spin permutation testing. The Results and Figure 6 legend were revised accordingly to describe the updated panels, loading z-scores, covariance explained, and associations between SUD-side latent variable scores and functional and structural cortical degree centrality. Minor wording changes were also made to align the interpretation of these analyses across the manuscript.
Data availability
All data reported in the manuscript are included in the article and its supplementary information files. Summary statistics of the case-control meta-analyses from the ENIGMA Working Groups are available from the ENIGMA Toolbox (https://enigma-toolbox.readthedocs.io/en/latest/).46 Preprocessed normative cortico-cortical, subcortico-cortical, and subcortico-subcortical functional and structural connectivity data are available from the ENIGMA Toolbox (https://enigma-toolbox.readthedocs.io/en/latest/). Molecular, connectivity, and receptor datasets are available from https://github.com/netneurolab/hansen_crossdisorder_vulnerability.git and https://github.com/netneurolab/hansen_receptors.git. Additional information can be made available upon reasonable request to the authors.
